Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.55 -0.27 (-0.86%)

Streaming Delayed Price Updated: 1:59 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 19, 2023

On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.

Via Investor's Business Daily

Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗

January 11, 2023

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

3 Biotech Companies to Watch in 2023 ↗

January 06, 2023

These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.

Via InvestorPlace

Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

December 21, 2022

From Genmab A/S

Via Business Wire

Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗

December 14, 2022

See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.

Via Investor's Business Daily

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

December 11, 2022

From Genmab A/S

Via Business Wire

Our 7 Top Biotech Stock Picks for 2023 ↗

December 09, 2022

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

Via InvestorPlace

BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating ↗

December 08, 2022

On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.

Via Investor's Business Daily

3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗

December 08, 2022

These companies have long runways of growth ahead

Via The Motley Fool

Is AbbVie Stock a Buy Now? ↗

December 06, 2022

The pharmaceutical company prepared well as Humira approaches its patent cliff next year.

Via The Motley Fool

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

November 29, 2022

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Friday ↗

November 25, 2022

On Friday, 68 companies reached new 52-week highs.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 01, 2022

During Thursday's session, 108 stocks hit new 52-week highs.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 21, 2022

During Monday's session, 50 stocks hit new 52-week highs.

Via Benzinga

Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

November 21, 2022

From Genmab

Via Business Wire

BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 ↗

November 11, 2022

The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.

Via Investor's Business Daily

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

November 03, 2022

From Genmab A/S

Via Business Wire

Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

October 28, 2022

From Genmab A/S

Via Business Wire

3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink ↗

October 25, 2022

You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 21, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark ↗

October 14, 2022

In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday.

Via Investor's Business Daily

Amgen Stock Shows Market Leadership With Jump To 90 RS Rating ↗

October 12, 2022

On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.

Via Investor's Business Daily

BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 10, 2022

On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.

Via Investor's Business Daily

Pacira Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 07, 2022

On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.

Via Investor's Business Daily

Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment ↗

September 27, 2022

Via Benzinga

Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating ↗

September 23, 2022

Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Via Investor's Business Daily

Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 14, 2022

Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.

Via Investor's Business Daily

Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗

September 09, 2022

On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.

Via Investor's Business Daily

Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗

September 09, 2022

Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.

Via Investor's Business Daily

Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

September 02, 2022

Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.

Via Investor's Business Daily

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.